[Form 4] Q32 Bio Inc. Insider Trading Activity
Rhea-AI Filing Summary
Q32 Bio Inc. reported that director Sven Ante Lundberg received a grant of stock options on January 15, 2026. The award covers 20,363 stock options to buy Q32 Bio common stock at an exercise price of $2.75 per share.
The options were granted under the company’s 2024 Stock Option and Incentive Plan and its non-employee director compensation policy, reflecting Lundberg’s election to receive options instead of cash retainer fees. The grant vests in four equal quarterly installments, each at the end of a calendar quarter, conditioned on continued board service. The filing notes the award was initially not reported due to administrative oversight.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Lundberg Sven Ante
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,363 | $2.75 | $56K |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,363 shares (Direct)
Footnotes (1)
- F1. This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.